Key insights
- Germany's healthcare reforms to cut costs and address a €40B deficit will squeeze pharmaceutical companies via higher rebates and prescription steering. This adds to pricing pressure from the US, potentially impacting pharmaceutical innovation and profitability. Insmed already halted a German launch. While focused on Europe, reduced pharma profitability and innovation could have a slightly negative ripple effect on US-listed pharma companies.
Investing.com -- Germany is moving to address a ballooning deficit in its public health-insurance funds through a series of aggressive cost-cutting measures that threaten the profitability of the global pharmaceutical industry.
Chancellor Friedrich Merz’s ruling coalition has introduced a package of reforms aimed at plugging a shortfall projected to reach €40 billion by 2030. The law, which Merz has hailed as “historic,” seeks to rein in a system that currently costs more than half a trillion euros annually.
The proposed legislation would significantly tighten pricing rules and drug spending. Under the new framework, drugmakers must provide higher rebates, which are set to rise to approximately 10.5% starting in 2027.
Furthermore, insurers will gain the authority to group similar patented medicines together to drive prescriptions toward lower-cost alternatives.
Han Steutel, president of the German pharma lobby VFA, noted in an interview that the measures will have the “worst impact we’ve seen so far,” predicting that jobs may migrate abroad while patients receive “the cheapest, rather than the best” medicines.
Concerns regarding European competitiveness are mounting as the sector simultaneously faces pressure from the U.S., where policy shifts aim to align domestic drug prices with lower international rates.
Some companies are already reacting to the uncertainty; Insmed Inc. recently opted against launching a new lung treatment in Germany.
Paola Casarosa, a board member at Boehringer Ingelheim GmbH, remarked that it is becoming “increasingly difficult to launch innovation in Europe,” expressing worry that aging populations may lose access to the latest medical breakthroughs.
Beyond the pharmaceutical sector, the reforms target hospitals, the primary cost driver in the German system. Plans include requiring second opinions for frequent operations and limiting reimbursements for rising staff costs.
The uncertainty has already impacted financial markets, with shares of private hospital operator Fresenius SE falling roughly 20% since February. Chief Executive Officer Michael Sen criticized the execution of the plan, describing it as a “missed opportunity” to fundamentally redesign a “chronically inefficient” system.